The Immunotherapy Cola Wars


It's been a big week for immunotherapy for lung cancer. Right on the heels of a press release that the PD-1 inhibitor Opdivo (nivolumab) significantly improved survival for patients with advanced non-squamous NSCLC, my friend Dr. Garon from UCLA presented results at the American Association for Cancer Research conference with another PD-1 inhibitor, Keytruda (pembrolizumab).

5 Key Points on Immune Checkpoint Inhibitors for Lung Cancer: Game Changer or Just Leveling Up?


Just last week, I ranked the development of immunotherapies as the leading development in lung cancer in 2013. I don't consider 2013 to be the clear turning point for immunotherapies in lung cancer: they have been the subject of interest and research for many years, and ASCO 2012 really marks their breakout from niche idea to more widespread credibility. But if 2012 was the real launchpad, 2013 saw the rocket really take off. The question is where is it really going?

Anti-PDL1 Immunotherapy MPDL3280A Observed to Be Particularly Active in Smokers with NSCLC


There are a few interesting new stories coming out of the 2013 European Society for Medical Oncology (ESMO) conference in Amsterdam that's just wrapping up today.  One has been on the  anti-PDL1 immunotherapy MPDL3280A, an agent from Roche that we saw some initial promising data on at ASCO 2013 earlier this year.  Dr.

Subscribe to MPDL3280A